Glancy Prongay & Murray LLP reminds investors to look forward


LOS ANGELES, October 10, 2022 (Globe Newswire) – Glancy Prongay & Murray LLP (“GPM”) reminds investors of the future November 21 2022 Deadline for filing the lead plaintiff’s class action suit on behalf of investors who purchased or purchased Fulgent Genetics, Inc. (“Fulgent” or “Company”) (NASDAQ: FLGT) between stock March 22, 2019 and August 4, 2022including (the “separation period”).

If you experience a loss on your investment in Fulgent or would like to inquire about the possibility of litigating your loss under federal securities laws, you may submit your contact information at www.glancylaw.com/cases/fulgent-genetics-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, toll-free at 888-773-9224, or by email at shareholders@glancylaw.com To find out more about your rights.

On August 4, 2022, Fulgent released its financial results for the second quarter of 2022, revealing that the Securities and Exchange Commission was investigating some of the 2018 Exchange Act reports through the first quarter of 2020. This came after the company received a civil investigation request issued by The US Department of Justice “relates to its investigation of allegations of medically unnecessary lab tests, incorrect billing of lab tests, and rewards received or provided in violation of the Anti-Bribery Act and the Stark Act.”

Based on this news, Fulgent’s stock fell $11.02, or 17.3%, over the next two trading sessions, to close at $52.72 a share on August 8, 2022, hurting investors.

The complaint filed in this class action lawsuit alleges that throughout the course of the class action, the defendants have made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, the defendants failed to disclose to investors that: (i) that Fulgent was conducting medically unnecessary laboratory tests, engaging in improper billing practices in connection with laboratory tests, and providing or receiving remuneration in violation of the Anti-Bribery Act and the law strict; (ii) Accordingly, Fulgent was likely to be subject to further legal and regulatory scrutiny; (3) Fulgent’s revenue, in so far as it was derived from prior unlawful conduct, was unsustainable; (iv) the foregoing, once disclosed, is likely to expose the company to significant financial and/or reputational damage; and (5) as a result, the defendants’ positive statements about the Company’s business, operations and prospects were materially misleading and/or lacking a reasonable basis at all relevant times.

Follow us for updates on LinkedInAnd the Twitteror Facebook.

If you purchase or acquire Fulgent securities during the period of the lawsuit, you may transfer court no later than November 21 2022 To request the appointment of the Lead Plaintiff in this presumed Class Action Suit. To be a member of a class action, you do not need to take any action at this time; You may have an attorney of your choice or take no action and remain an absentee member of the class action. If you would like to learn more about this class action, or if you have any questions regarding this advertisement or your rights or interests in connection with a pending class action suit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 at 310-201-9150, toll-free at 888-773-9224, emailed to shareholders@glancylaw.comor visit our website at www.glancylaw.com. If you are inquiring by e-mail, please include your postal address, telephone number, and the number of shares purchased.

This press release may be considered an attorney’s notice in some jurisdictions under applicable law and ethical rules.

Contacts
Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com


Leave a Reply

Your email address will not be published. Required fields are marked *